Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teresa Field

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
International Journal of Hematology|January 20, 2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complicationsJoseph Pidala, Jaime Roman-Diaz, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 11, 2011
ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantationJoseph Pidala, Marcie Tomblyn, Taiga Nishihori, et al.
Bone Marrow Transplantation|April 20, 2018
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host diseaseLia Perez, Hugo Fernandez, Pedro Horna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 2, 2013
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allograftingMohamed A Kharfan-Dabaja, Claudio Anasetti, Hugo F Fernandez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2015
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial resultsJoseph Pidala, Jongphil Kim, Brian C Betts, et al.
Haematologica|April 5, 2015
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseJoseph Pidala, Jongphil Kim, Melissa Alsina, et al.
Leukemia Research|July 15, 2011
Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature reviewJane Jijun Liu, Ling Zhang, Ernesto Ayala, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 9, 2017
TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic SyndromeMohamed A Kharfan-Dabaja, Rami S Komrokji, Qing Zhang, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Hematology|January 20, 2011
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complicationsJoseph Pidala, Jaime Roman-Diaz, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 11, 2011
ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantationJoseph Pidala, Marcie Tomblyn, Taiga Nishihori, et al.
Bone Marrow Transplantation|April 20, 2018
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host diseaseLia Perez, Hugo Fernandez, Pedro Horna, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 2, 2013
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allograftingMohamed A Kharfan-Dabaja, Claudio Anasetti, Hugo F Fernandez, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2015
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial resultsJoseph Pidala, Jongphil Kim, Brian C Betts, et al.
Haematologica|April 5, 2015
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseJoseph Pidala, Jongphil Kim, Melissa Alsina, et al.
Leukemia Research|July 15, 2011
Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature reviewJane Jijun Liu, Ling Zhang, Ernesto Ayala, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2010
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromeMohamed A Kharfan-Dabaja, Julio C Chavez, Daohai Yu, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 9, 2017
TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic SyndromeMohamed A Kharfan-Dabaja, Rami S Komrokji, Qing Zhang, et al.
Pageof 4